Abstract
Pancreatic cancer is characterized by extremely poor prognosis because of early recurrence and metastasis, and increasing evidence supports the critical role of microRNA in cancer progression. Here we identified that microRNA-34b functioned as a tumor-suppressing microRNA by targeting oncogenic Smad3 in pancreatic cancer. As a hypovascular tumor with a potential endoplasmic reticulum stress microenvironment, miR-34b was silenced after ER stress inducer thapsigargin (Tg) treatment and negatively regulated by ER stress chaperone glucose regulated protein 78 (GRP78) in pancreatic cancer cells. In human specimens, we found that miR-34b was down-regulated in pancreatic cancer tissues and low level of miR-34b expression was positively correlated with tumor-node-metastasis (TNM) stage, lymph-node metastasis and overall survival. Functional assays showed that over-expression of miR-34b inhibited pancreatic cancer progression in vitro and in vivo. In addition, Smad3 was demonstrated as a direct target of miR-34b and negatively regulated by miR- 34b at mRNA and protein levels. Luciferase assays confirmed that miR-34b could directly bind to the 3’untranslated region of Smad3. An inverse correlation between miR-34b and Smad3 was observed in 64 pancreatic cancer tissues. Our findings indicate that miR-34b acts as a tumor metastasis suppressor through negatively modulating Smad3, which may provide a potential therapeutic strategy for pancreatic cancer.
Keywords: EMT, endoplasmic reticulum stress, microRNA-34b, pancreatic cancer, Smad3, tumor suppressor
Current Molecular Medicine
Title:MicroRNA-34b Inhibits Pancreatic Cancer Metastasis Through Repressing Smad3
Volume: 13 Issue: 4
Author(s): Y. Lu, X. Yu, M. Li, J. Xu, J. Long, L. Liu, Y. Qin, W. Yao, C. Wu, C. Liu, X. Cai, P. Cen, L. Chen, J. Yang, X. Cui, S. Shi and H. Cheng
Affiliation:
Keywords: EMT, endoplasmic reticulum stress, microRNA-34b, pancreatic cancer, Smad3, tumor suppressor
Abstract: Pancreatic cancer is characterized by extremely poor prognosis because of early recurrence and metastasis, and increasing evidence supports the critical role of microRNA in cancer progression. Here we identified that microRNA-34b functioned as a tumor-suppressing microRNA by targeting oncogenic Smad3 in pancreatic cancer. As a hypovascular tumor with a potential endoplasmic reticulum stress microenvironment, miR-34b was silenced after ER stress inducer thapsigargin (Tg) treatment and negatively regulated by ER stress chaperone glucose regulated protein 78 (GRP78) in pancreatic cancer cells. In human specimens, we found that miR-34b was down-regulated in pancreatic cancer tissues and low level of miR-34b expression was positively correlated with tumor-node-metastasis (TNM) stage, lymph-node metastasis and overall survival. Functional assays showed that over-expression of miR-34b inhibited pancreatic cancer progression in vitro and in vivo. In addition, Smad3 was demonstrated as a direct target of miR-34b and negatively regulated by miR- 34b at mRNA and protein levels. Luciferase assays confirmed that miR-34b could directly bind to the 3’untranslated region of Smad3. An inverse correlation between miR-34b and Smad3 was observed in 64 pancreatic cancer tissues. Our findings indicate that miR-34b acts as a tumor metastasis suppressor through negatively modulating Smad3, which may provide a potential therapeutic strategy for pancreatic cancer.
Export Options
About this article
Cite this article as:
Lu Y., Yu X., Li M., Xu J., Long J., Liu L., Qin Y., Yao W., Wu C., Liu C., Cai X., Cen P., Chen L., Yang J., Cui X., Shi S. and Cheng H., MicroRNA-34b Inhibits Pancreatic Cancer Metastasis Through Repressing Smad3, Current Molecular Medicine 2013; 13 (4) . https://dx.doi.org/10.2174/1566524011313040001
DOI https://dx.doi.org/10.2174/1566524011313040001 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Phosphoinositide 3-Kinases and Leukocyte Migration
Current Immunology Reviews (Discontinued) Key Epigenetic Events Involved in the Maintenance of Breast Cancer Stem Cells
Current Stem Cell Research & Therapy Anti-Amyloidogenic and Anti-Apoptotic Role of Melatonin in Alzheimer Disease
Current Neuropharmacology Apoptosis and Autophagy Induction As Mechanism of Cancer Prevention by Naturally Occurring Dietary Agents
Current Drug Targets Small Molecules for Immunomodulation in Cancer: A Review
Anti-Cancer Agents in Medicinal Chemistry Subject Index To Volume-3
Letters in Drug Design & Discovery Fluorescence Molecular Imaging of Small Animal Tumor Models
Current Molecular Medicine Co-targeting EGFR and Autophagy Impairs Ovarian Cancer Cell Survival during Detachment from the ECM
Current Cancer Drug Targets Molecular Approaches Target to Immunotherapy for HPV-Associated Cancers
Current Cancer Drug Targets Antidepressant Desipramine Leads to C6 Glioma Cell Autophagy: Implication for the Adjuvant Therapy of Cancer
Anti-Cancer Agents in Medicinal Chemistry Combining Cytotoxic and Immune-Mediated Gene Therapy to Treat Brain Tumors
Current Topics in Medicinal Chemistry Hitting a Moving Target: Glioma Stem Cells Demand New Approaches in Glioblastoma Therapy
Current Cancer Drug Targets Transporters at CNS Barrier Sites: Obstacles or Opportunities for Drug Delivery?
Current Pharmaceutical Design Factors Affecting the Metabolite Productions in Endophytes: Biotechnological Approaches for Production of Metabolites
Current Medicinal Chemistry 1,3,4-Thiadiazole Based Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Compounds from Wild Mushrooms with Antitumor Potential
Anti-Cancer Agents in Medicinal Chemistry Cell Cycle and Cancer: The G1 Restriction Point and the G1 / S Transition
Current Genomics Bioactive Heterocyclic Compounds as Potential Therapeutics in the Treatment of Gliomas: A Review
Anti-Cancer Agents in Medicinal Chemistry Nuclear Long Non-Coding RNAs as Epigenetic Regulators in Cancer
Current Medicinal Chemistry Editorial (BIOQUEST India: A Global Biotechnology Forum for Knowledge-Based Innovation and Sustainable Development)
Current Pharmacogenomics and Personalized Medicine